PDCD1 and melanoma: One important trial for relatlimab evaluation is RELATIVITY-047, a Phase III trial that evaluated the effect of inhibiting both LAG-3 and PD-1 by the combination of relatlimab and nivolumab compared with the effect of nivolumab alone for patients with untreated metastatic or unresectable melanoma (NCT03470922).